1. Market Research
  2. > Laurantis Pharma Oy - Product Pipeline Review - 2013

Laurantis Pharma Oy - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 27 pages

Laurantis Pharma Oy - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Laurantis Pharma Oy - Product Pipeline Review - 2013” provides data on the Laurantis Pharma Oy’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Laurantis Pharma Oy’s corporate website, SEC filings, investor presentations and featured press releases, both from Laurantis Pharma Oy and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Laurantis Pharma Oy - Brief Laurantis Pharma Oy overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Laurantis Pharma Oy human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Laurantis Pharma Oy with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Laurantis Pharma Oy’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Laurantis Pharma Oy’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Laurantis Pharma Oy in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Laurantis Pharma Oy’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Laurantis Pharma Oy.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Laurantis Pharma Oy and identify potential opportunities in those areas.

Table Of Contents

Laurantis Pharma Oy - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Laurantis Pharma Oy Snapshot 4
Laurantis Pharma Oy Overview 4
Key Information 4
Key Facts 4
Laurantis Pharma Oy - Research and Development Overview 5
Key Therapeutic Areas 5
Laurantis Pharma Oy - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Laurantis Pharma Oy - Pipeline Products Glance 9
Laurantis Pharma Oy Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Laurantis Pharma Oy - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Laurantis Pharma Oy - Drug Profiles 12
Lymfactin 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
ProtoCure Emulsion Cream 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
ProtoCure Eye Drops 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
ProtoCure Intravesical Instillation Solution 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Laurantis Pharma Oy - Pipeline Analysis 19
Laurantis Pharma Oy - Pipeline Products by Therapeutic Class 19
Laurantis Pharma Oy - Pipeline Products by Route of Administration 21
Laurantis Pharma Oy - Recent Pipeline Updates 22
Laurantis Pharma Oy - Dormant Projects 24
Laurantis Pharma Oy - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables


Laurantis Pharma Oy, Key Information 4
Laurantis Pharma Oy, Key Facts 4
Laurantis Pharma Oy - Pipeline by Indication, 2013 6
Laurantis Pharma Oy - Pipeline by Stage of Development, 2013 7
Laurantis Pharma Oy - Monotherapy Products in Pipeline, 2013 8
Laurantis Pharma Oy - Phase II, 2013 9
Laurantis Pharma Oy - Phase I, 2013 10
Laurantis Pharma Oy - Preclinical, 2013 11
Laurantis Pharma Oy - Pipeline By Therapeutic Class, 2013 20
Laurantis Pharma Oy - Pipeline By Route of Administration, 2013 21
Laurantis Pharma Oy - Recent Pipeline Updates, 2013 22
Laurantis Pharma Oy - Dormant Developmental Projects,2013 24

List of Figures


Laurantis Pharma Oy - Pipeline by Indication, 2013 6
Laurantis Pharma Oy - Pipeline by Stage of Development, 2013 7
Laurantis Pharma Oy - Monotherapy Products in Pipeline, 2013 8
Laurantis Pharma Oy - Pipeline By Therapeutic Class, 2013 19
Laurantis Pharma Oy - Pipeline By Route of Administration, 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.